SYNCAR-002/STK-009

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameSYNCAR-002/STK-009

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionAnti-Glypican-3Interleukin-2 receptor agonists

TargetsGlypican-3Interleukin-2 receptor

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSynthekine Inc

China Registration ClassN/A

Develop Information

Active CompaniesSynthekine Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A